Quoin Pharmaceuticals (QNRX) Institutional Ownership $8.56 +0.16 (+1.90%) Closing price 07/24/2025 03:59 PM EasternExtended Trading$8.58 +0.02 (+0.22%) As of 07:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Quoin Pharmaceuticals (NASDAQ:QNRX)CurrentInstitutional OwnershipPercentage8.63%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$12.24MNumber ofInstitutional Sellers(last 12 months)0 Get QNRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Quoin Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data QNRX Institutional Buying and Selling by Quarter Quoin Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2025Boothbay Fund Management LLC80,712$53K0.0%N/A1.598% 2/14/2025Altium Capital Management LLC282,249$184K0.1%N/A5.589% 2/13/2025Renaissance Technologies LLC133,122$87K0.0%+244.1%2.636% 1/28/2025Apollon Wealth Management LLC80,025$52K0.0%N/A1.585% 5/20/2024Virtu Financial LLC30,749$29K0.0%N/A0.773% 5/1/2023Virtu Financial LLC147,907$70K0.0%N/A3.050% 11/7/2022Virtu Financial LLC29,865$67K0.0%N/A2.948% (Data available from 1/1/2016 forward) QNRX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of QNRX shares? During the previous two years, the following institutional investors and hedge funds held shares of Quoin Pharmaceuticals shares: Altium Capital Management LLC ($184K), Renaissance Technologies LLC ($87K), Boothbay Fund Management LLC ($53K), and Apollon Wealth Management LLC ($52K), Virtu Financial LLC ($29K).Learn more on Quoin Pharmaceuticals' institutional investors. What percentage of Quoin Pharmaceuticals' stock is owned by institutional investors? 8.63% of Quoin Pharmaceuticals' stock is owned by institutional investors. Learn more on QNRX's institutional investor holdings. Which institutional investors have been buying Quoin Pharmaceuticals' stock? The following institutional investors have purchased Quoin Pharmaceuticals' stock in the last 24 months: Altium Capital Management LLC ($282.25K), Renaissance Technologies LLC ($94.43K), Boothbay Fund Management LLC ($80.71K), Apollon Wealth Management LLC ($80.03K), and Virtu Financial LLC ($30.75K). How much institutional buying is happening at Quoin Pharmaceuticals? Institutional investors have bought a total of 537,417 shares in the last 24 months. This purchase volume represents approximately $12.24M in transactions. Related Companies NXGL Institutional Ownership NXL Institutional Ownership NRXS Institutional Ownership IRIX Institutional Ownership IINN Institutional Ownership PSTV Institutional Ownership MHUA Institutional Ownership INBS Institutional Ownership WOK Institutional Ownership DHAI Institutional Ownership This page (NASDAQ:QNRX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Quoin Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
